Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556873 | 0.89 | ADAMTS5 (0.33) | ADAMTS5CHRNB2ADRA2CCHRNB4CHRNA3 | |
| SCHEMBL557596 | 0.80 | HTR2A (0.37) | ADAMTS5CHRNB2ADRA2CCHRNB4CHRNA3 | |
| SCHEMBL555599 | 0.69 | SLC6A2 (0.32) | — | |
| SCHEMBL556599 | 0.69 | CYP1A2 (0.35) | HTR2AHTR2CHTR2B | |
| SCHEMBL30569759 | 0.64 | KDM1A (0.37) | ADAMTS5KDM1AHTR2AHTR2CHTR2B | |
| SCHEMBL1974159 | 0.61 | KDM1A (0.40) | ADAMTS5KDM1AHTR2AHTR2CHTR2B | |
| SCHEMBL2479416 | 0.61 | KDM1A (0.40) | KDM1AHTR2AHTR2CHTR2B | |
| SCHEMBL376322 | 0.60 | — | — | |
| SCHEMBL4885909 | 0.60 | — | — | |
| SCHEMBL3947021 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | ADAMTS5 496/4885CHRNB2 4697/4885ADRA2C 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.